Login / Signup

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.

Johannes M WellerN SchäferC SchaubTheophilos TzaridisT ZeyenMatthias SchneiderAnna-Laura PotthoffF A GiordanoJ P SteinbachP S ZeinerT KowalskiM SabelP HauD KrexO GrauerR GoldbrunnerO SchnellGhazaleh TabatabaiFlorian RingelF Schmidt-GrafS BrehmerJ C TonnL BullingerP VajkoczyM GlasH VatterU HerrlingerC Seidel
Published in: Journal of neuro-oncology (2023)
NCT01149109.
Keyphrases
  • high grade
  • low grade
  • newly diagnosed
  • study protocol
  • phase iii
  • clinical trial
  • phase ii
  • open label